Immix Biopharma, Inc. has reported significant financial developments in its recent 10-K filing for the fiscal year ending December 31, 2025. The company, which specializes in chimeric antigen receptor T-cell (CAR-T) therapies, particularly for AL Amyloidosis, recorded a net loss of $29.4 million, an increase from a loss of $21.7 million in the previous year. This rise in losses is attributed to heightened research and development expenses, which surged to $16.3 million from $11.3 million, reflecting ongoing clinical trials and related costs. General and administrative expenses also rose to $13.7 million, up from $11.4 million, primarily due to increased staffing and professional services.
In terms of liquidity, Immix Biopharma reported total assets of approximately $104.8 million as of December 31, 2025, a substantial increase from $22.9 million the previous year. This growth was largely fueled by successful capital raises, including a public offering in December 2025 that generated approximately $100 million in gross proceeds. The company also completed a private placement in September 2025, raising about $9.3 million. As of the end of 2025, the company had cash and cash equivalents of $93.9 million, which it believes will support its operations for at least the next 12 months.
Strategically, Immix Biopharma has made notable advancements in its clinical programs. The lead candidate, NXC-201, has received multiple designations from the FDA, including Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations, which are expected to expedite its development and review process. The company is currently conducting two clinical trials, NEXICART-1 and NEXICART-2, aimed at evaluating NXC-201's efficacy in treating relapsed/refractory AL Amyloidosis. Recent interim results from these trials have shown promising response rates, with complete responses observed in 75% of patients treated.
Operationally, the company has expanded its workforce to support its growing clinical and administrative needs, with a total of 21 employees as of March 2026. The company has also entered into a long-term lease for biopharmaceutical manufacturing space in California, which is expected to enhance its production capabilities. However, Immix Biopharma acknowledges the ongoing risks associated with its clinical trials, including potential delays in patient enrollment and the need for additional funding to sustain its operations and development efforts.
Looking ahead, Immix Biopharma anticipates continued operating losses as it invests heavily in research and development. The company plans to seek additional financing through various means, including equity and debt offerings, to support its clinical programs and operational needs. Despite the challenges, the company remains focused on advancing its product candidates and achieving regulatory approvals, which are critical for its long-term success and potential revenue generation.
About Immix Biopharma, Inc.
Immix Biopharma is a clinical-stage biopharmaceutical company developing innovative cell therapies, primarily CAR-T, for light chain (AL) Amyloidosis and immune-mediated diseases. Its lead candidate, NXC-201, targets relapsed/refractory AL Amyloidosis, with ongoing clinical trials and regulatory designations including Orphan Drug and RMAT. The company focuses on leveraging proprietary platforms to create accessible, targeted treatments for serious, underserved conditions.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.